Highlights
- ResMed was priced at A$30.74 on 9 September 2026, keeping investor attention on the operating trends that could influence the next leg of the share story.
- FY26 Revenue increased 10% to US$5.65 billion, led by growth across devices, masks and other sleep and breathing health products.
- The company is sharpening its focus on sleep, breathing and connected home-based healthcare through portfolio changes and digital-health investment.
- Competition, reimbursement settings, regulatory requirements and supply-chain execution remain important factors for investors to monitor.
ResMed (ASX:RMD) sits at the intersection of medical devices, sleep health and digital healthcare. At the time of writing on 9 September 2026, the shares were priced at A$30.74. For investors, the more durable question is how operating growth, product adoption and portfolio execution translate into Earnings momentum over time
Sleep Health at the Core
ResMed designs and sells cloud-connected devices and software used in sleep apnea, respiratory care and home-based healthcare. Its portfolio includes CPAP and APAP systems, masks, ventilation products, diagnostic tools and digital platforms such as AirView and myAir. The company sells in more than 140 countries, giving it a broad geographic base across the Americas and international markets
What the Numbers Show
FY26 net revenue rose 10% to US$5.65 billion from US$5.15 billion a year earlier. Sleep and Breathing Health revenue increased to US$4.98 billion, while Residential Care Software revenue reached US$675.8 million. Net Income rose to US$1.52 billion from US$1.40 billion, and Operating Cash Flow was US$1.8 billion. These figures provide a useful backdrop for assessing whether the Business can continue converting product Demand into earnings and cash generation.
Products and Digital Reach
Product breadth remains central to ResMed’s Investment case. Devices accounted for roughly 51% of FY26 revenue, while masks, diagnostic products and accessories represented about 37%. The company is also building a larger connected-care ecosystem around remote monitoring, patient engagement and therapy management. AirView and myAir support clinicians and patients beyond the initial device sale, creating an increasingly digital layer around ResMed’s core hardware platform.
Portfolio Focus
ResMed has also been reshaping its portfolio. In June 2026, it acquired Noctrix Health, adding an FDA De Novo-classified wearable therapy for restless legs syndrome. Separately, the company agreed to sell MatrixCare for US$490 million in cash, with the transaction expected to close in the first quarter of FY27. The moves point to a sharper emphasis on sleep health, breathing health and connected home-based care.
What Could Move Sentiment
For the share story, investors may watch growth in devices and masks, adoption of newer connected products, margins, cash conversion and progress in adjacent sleep-health markets. The company’s ability to use digital tools to improve adherence and simplify care pathways may also influence the long-term quality of revenue growth. At the same time, portfolio changes create execution questions around Capital allocation and the mix of future earnings.
Risks on the Radar
ResMed operates in a heavily regulated healthcare market and depends on reimbursement frameworks across multiple countries. Competition in sleep and breathing devices remains intense, while alternative therapies, including pharmaceutical treatments for obesity and obstructive sleep apnea, could alter treatment pathways over time. Supply-chain disruption, tariffs, data-privacy obligations, product regulation and Cybersecurity are additional risks that could affect costs, demand or execution.
Conclusion
ResMed combines an established sleep and breathing health Franchise with an expanding digital-health platform and a more focused portfolio. With the shares at A$30.74 on 9 September 2026, the next phase of investor attention is likely to centre on whether FY26 growth can be sustained through product adoption, connected-care expansion and disciplined portfolio execution. Revenue growth, margins, cash flow and competitive developments remain the key markers to watch.
